| Literature DB >> 32442188 |
Maria Arroyo1, Kyle Salka1, Elizabeth Chorvinsky1, Xilei Xuchen1, Karima Abutaleb1, Geovanny F Perez1, Jered Weinstock2, Susana Gaviria1, Maria J Gutierrez1, Gustavo Nino1,3.
Abstract
BACKGROUND: MicroRNAs (miRs) control gene expression and the development of the immune system and antiviral responses. MiR-155 is an evolutionarily-conserved molecule consistently induced during viral infections in different cell systems. Notably, there is still an unresolved paradox for the role of miR-155 during viral respiratory infections. Despite being essential for host antiviral TH1 immunity, miR-155 may also contribute to respiratory disease by enhancing allergic TH2 responses and NFkB-mediated inflammation. The central goal of this study was to define how airway miR-155 production is related to TH1, TH2, and pro-inflammatory cytokine responses during naturally occurring viral respiratory infections in young children.Entities:
Year: 2020 PMID: 32442188 PMCID: PMC7244143 DOI: 10.1371/journal.pone.0233352
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Nasal airway miR-155 levels according to respiratory viruses in young children.
RSV = human respiratory syncytial virus, RV = human rhinovirus, HMPV = human metapneumovirus. *Virus frequency includes single and mixed viral infections. ** miR-155 levels calculated with ΔΔCt method normalized to a spike in control (cel-miR-39) and presented as median and IQR. ***p values relative to miR-155 values in the control (uninfected) group. No significant differences were observed in miR-155 levels according to virus (Kruskal Wallis p = 0.83).
| Virus | N* | Nasal miR-155 levels** | p-value*** |
|---|---|---|---|
| 11 | 1.33 (0.1–3.8) | Reference | |
| 140 | 7.04 (1.6–37.9) | 0.004 | |
| 32 | 10.8 (1.4–34) | 0.008 | |
| 82 | 4.56 (1.3–32.8) | 0.014 | |
| 19 | 14.2 (3.4–234) | 0.004 | |
| 10 | 3.53 (1.2–21.8) | 0.14 | |
| 10 | 25.3 (3.6–94) | 0.04 | |
| 22 | 5.8 (1.3–39) | 0.02 | |
| 36 | 4.54 (1.7–46.5) | 0.01 |
Baseline characteristics of study subjects: VRI = viral respiratory infection, RSV = human respiratory syncytial virus, RV = human rhinovirus, HMPV = human metapneumovirus.
*Percentage of each virus includes single and mixed viral infections.**p values obtained by Kruskal-Wallis test for continuous variables and logistic regression for binary variables (RV reference group for viral pathogens).
| Variable | Controls | VRI High miR-155 | VRI Medium miR-155 | VRI Low miR-155 | **p-value |
|---|---|---|---|---|---|
| 11 | 35 | 70 | 35 | - | |
| 0.81 | 0.99 | 1.13 | 1.11 | 0.36 | |
| 63 | 60 | 65 | 60 | 0.94 | |
| 64 | 46 | 59 | 66 | 0.77 | |
| 40 | 31 | 50 | 48 | 0.18 | |
| - | 63 | 60 | 51 | 0.59 | |
| - | 25 | 23 | 20 | 0.94 | |
| - | 17 | 16 | 14 | 0.85 | |
| - | 9 | 9 | 3 | 0.52 | |
| - | 3 | 7 | 11 | 0.77 | |
| - | 6 | 13 | 23 | 0.10 | |
| - | 23 | 25 | 28 | 0.97 |
Fig 1Nasal miR-155 levels stratified as high (>75th%ile), medium (25-75th%ile), or low (<25th%ile) demonstrate that young children with high miR-155 levels during viral respiratory infections (green boxplots) have higher airway production of (A) IFN-γ, (C) TNF- α, (C) IL-1β, (D) IL-4 and (E) IL-13.
Fig 2Nasal miR-155 levels stratified as high (>75th%ile), medium (25-75th%ile), or low (<25th%ile) demonstrate that young children with high miR-155 levels during viral respiratory infections (green boxplots) have higher airway TH1 cytokine polarization (IFN-γ:IL-4 ratios, calculated with protein concentration pg/ml).
Fig 3Individuals with a high TH1 polarization profile (IFN-γ:IL-4 ratios >75th%tile; red boxplots; n = 34) have a distinct airway molecular signature characterized by higher nasal miR-155 levels and increased nasal protein levels of pro-inflammatory cytokines (TNF-α, IL-1β) relative to the rest of study subjects (IFN-γ:IL-4 ratios ≤75th percentile; yellow boxplots; n = 106).
Nasal levels (y axis) correspond to protein concentration (pg/ml) for TNF-α, IL-1β and to normalized expression for miR-155 (ΔΔCt method normalized to a spike in control cel-miR-39).
Airway miR-155, TH1 responses and clinical severity during viral respiratory infections.
RV = human rhinovirus, RSV = human respiratory syncytial virus. *High TH1 group defined as IFN-γ:IL-4 ratios >75th%tile, **Regression model adjusted by age and RSV status.
| High TH1 group (n = 34)* | Non-high TH1 group (n = 106) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Adj. Model** | Univariate | Adj. Model** | |||||||
| Respiratory severity score | Effect estimate (β) | p-value | Effect estimate (β) | p-value | Respiratory severity score | Effect estimate (β) | p-value | Effect estimate (β) | p-value |
| -0.005 | -0.005 | 0.002 | 0.47 | 0.002 | 0.46 | ||||
| -0.0004 | -0.0004 | -0.0004 | 0.24 | -0.006 | 0.11 | ||||
| 0 | 0.96 | 0 | 0.98 | -0.0003 | 0.52 | -0.0003 | 0.43 | ||
| -0.0007 | 0.54 | -0.001 | 0.21 | -0.0001 | 0.88 | -0.0001 | 0.82 | ||
| -1.31 | 0.15 | -1.64 | -0.58 | 0.14 | -0.53 | 0.18 | |||
| -1.13 | 0.32 | -0.73 | 0.49 | 0.73 | 0.28 | 0.71 | 0.29 | ||
| 3.31 | 3.0 | -1.005 | 0.123 | -0.96 | 0.14 | ||||
| 3.8 | 3.07 | 0.961 | 0.138 | 1.27 | 0.05 | ||||
| 0.90 | 0.44 | 1.28 | 0.28 | -1.2 | 0.07 | -1.2 | 0.06 | ||
| 2.60 | 0.09 | 3.49 | 0.92 | 0.28 | 0.78 | 0.36 | |||